Anthracyclines: what does one do?
"Then Dr. Slamon's closer inspection found that not all Her2 patients are alike — and only those who have a second overactive gene, called TopoII, derive special benefit from anthracyclines. That's about 8 percent of breast cancer patients."
The above quote is from an article I read recently, probably on this site. My question is, if you find out that someone recently diagnosed with breast cancer will begin treatment with an anthracycline, do you point out the recent research or do you keep quiet? I did extensive research before I began my treatment and rejected adriamycin up front, but not all women have the time to do the same. I have no medical credentials and I don't feel I have any right to issue recommendations if not asked specifically, yet there's a part of me that thinks I have a moral obligation to point people to the latest research. Since Anthracyclines are particularly tough on the heart and are also, I believe, the main culprits in women who later get blood cancers I really don't know what to do, and it's been bothering me quite a bit. What would you do?
|